IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i23p16090-d990635.html
   My bibliography  Save this article

Programmatic Cost-Effectiveness of a Second-Time Visit to Detect New Tuberculosis and Diabetes Mellitus in TB Contact Tracing in Myanmar

Author

Listed:
  • Nyi Nyi Zayar

    (Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand)

  • Rassamee Chotipanvithayakul

    (Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand)

  • Kyaw Ko Ko Htet

    (Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand)

  • Virasakdi Chongsuvivatwong

    (Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand)

Abstract

Background: Integration of diabetes mellitus screening in home visits for contact tracing for tuberculosis could identify hidden patients with either tuberculosis or diabetes mellitus. However, poor compliance to the first home screening has been reported. A second time visit not only increases screening compliance but also the cost. This study aimed to determine if an additional second time visit was cost effective based on the health system perspective of the tuberculosis contact tracing program in Myanmar. Methods: This cross-sectional study was based on usual contact tracing activity in the Yangon Region, Myanmar, from April to December 2018 with integration of diabetes mellitus screening and an additional home visit to take blood glucose tests along with repeated health education and counseling to stress the need for a chest X-ray. New tuberculosis and diabetes mellitus cases detected were the main outcome variables. Programmatic operational costs were calculated based on a standardized framework for cost evaluation on tuberculosis screening. The effectiveness of an additional home visit was estimated using disability-adjusted life years averted. The willingness to pay threshold was taken as 1250.00 US dollars gross domestic product per capita of the country. Results: Single and additional home visits could lead to 42.5% and 65.0% full compliance and 27.2 and 9.3 additional years of disability-adjusted life years averted, respectively. The respective base costs and additional costs were 3280.95 US dollars and 1989.02 US dollars. The programmatic costs for an extra unit of disability-adjusted life years averted was 213.87 US dollars, which was lower than the willingness to pay threshold. Conclusions: From the programmatic perspective, conducting the second time visit for tuberculosis contact tracing integrated with diabetes mellitus screening was found to be cost effective.

Suggested Citation

  • Nyi Nyi Zayar & Rassamee Chotipanvithayakul & Kyaw Ko Ko Htet & Virasakdi Chongsuvivatwong, 2022. "Programmatic Cost-Effectiveness of a Second-Time Visit to Detect New Tuberculosis and Diabetes Mellitus in TB Contact Tracing in Myanmar," IJERPH, MDPI, vol. 19(23), pages 1-12, December.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:23:p:16090-:d:990635
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/23/16090/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/23/16090/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Gray, Alastair M. & Clarke, Philip M. & Wolstenholme, Jane L. & Wordsworth, Sarah, 2010. "Applied Methods of Cost-effectiveness Analysis in Healthcare," OUP Catalogue, Oxford University Press, number 9780199227280.
    2. Anna Vassall & Sanne van Kampen & Hojoon Sohn & Joy S Michael & K R John & Saskia den Boon & J Lucian Davis & Andrew Whitelaw & Mark P Nicol & Maria Tarcela Gler & Anar Khaliqov & Carlos Zamudio & Mar, 2011. "Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis," PLOS Medicine, Public Library of Science, vol. 8(11), pages 1-14, November.
    3. Anthony J. Hatswell & Ash Bullement & Andrew Briggs & Mike Paulden & Matthew D. Stevenson, 2018. "Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models," PharmacoEconomics, Springer, vol. 36(12), pages 1421-1426, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ewan M. Tomeny & Thomas Hampton & Phuong Bich Tran & Laura Rosu & Mphatso D. Phiri & Kathryn A. Haigh & Jasper Nidoi & Tom Wingfield & Eve Worrall, 2024. "Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses," PharmacoEconomics, Springer, vol. 42(11), pages 1209-1236, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Frank G. Sandmann & Julie V. Robotham & Sarah R. Deeny & W. John Edmunds & Mark Jit, 2018. "Estimating the opportunity costs of bed‐days," Health Economics, John Wiley & Sons, Ltd., vol. 27(3), pages 592-605, March.
    2. J. Jayasekera & E. Onukwugha & K. Bikov & C. Mullins & B. Seal & A. Hussain, 2014. "The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer," PharmacoEconomics, Springer, vol. 32(2), pages 173-191, February.
    3. Ernst, Richard, 2017. "Theories of Health Care Cost-Effectiveness Analysis," SocArXiv gjbcp, Center for Open Science.
    4. Anna H van’t Hoog & Frank Cobelens & Anna Vassall & Sanne van Kampen & Susan E Dorman & David Alland & Jerrold Ellner, 2013. "Optimal Triage Test Characteristics to Improve the Cost-Effectiveness of the Xpert MTB/RIF Assay for TB Diagnosis: A Decision Analysis," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-11, December.
    5. David Lairson & Rohan Parikh & Janice Cormier & Wenyaw Chan & Xianglin Du, 2014. "Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer," PharmacoEconomics, Springer, vol. 32(10), pages 1005-1013, October.
    6. Michael Lebenbaum & Joyce Cheng & Claire Oliveira & Paul Kurdyak & Juveria Zaheer & Rebecca Hancock-Howard & Peter C. Coyte, 2020. "Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada," Applied Health Economics and Health Policy, Springer, vol. 18(2), pages 189-201, April.
    7. Jun Li & Benjamin H K Yip & Chichiu Leung & Wankyo Chung & Kin On Kwok & Emily Y Y Chan & Engkiong Yeoh & Puihong Chung, 2018. "Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-18, January.
    8. Alice Zwerling & Richard G White & Anna Vassall & Ted Cohen & David W Dowdy & Rein M G J Houben, 2014. "Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-8, October.
    9. Afschin Gandjour & Amiram Gafni, 2013. "Internal validation of models with several interventions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 901-909, December.
    10. Rulof P. Burger & Zoë M. McLaren, 2017. "An econometric method for estimating population parameters from non‐random samples: An application to clinical case finding," Health Economics, John Wiley & Sons, Ltd., vol. 26(9), pages 1110-1122, September.
    11. Emma McManus, 2024. "Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model," PharmacoEconomics - Open, Springer, vol. 8(4), pages 569-583, July.
    12. Eric Kaun Santos Silva & June Alisson Westarb Cruz & Maria Alexandra Viegas Cortez Cunha & Thyago Proença Moraes & Sandro Marques & Eduardo Damião Silva, 2021. "Cost-effectiveness in health: consolidated research and contemporary challenges," Palgrave Communications, Palgrave Macmillan, vol. 8(1), pages 1-10, December.
    13. Edward C. F. Wilson & George Stanley & Zulfiquar Mirza, 2016. "The Long-Term Cost to the UK NHS and Social Services of Different Durations of IV Thiamine (Vitamin B1) for Chronic Alcohol Misusers with Symptoms of Wernicke’s Encephalopathy Presenting at the Emerge," Applied Health Economics and Health Policy, Springer, vol. 14(2), pages 205-215, April.
    14. Giuseppe Turchetti & S. Bellelli & M. Amato & S. Bianchi & P. Conti & A. Cupisti & V. Panichi & A. Rosati & F. Pizzarelli, 2017. "The social cost of chronic kidney disease in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 847-858, September.
    15. Anna Vassall & Lindsay Mangham‐Jefferies & Gabriela B. Gomez & Catherine Pitt & Nicola Foster, 2016. "Incorporating Demand and Supply Constraints into Economic Evaluations in Low‐Income and Middle‐Income Countries," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 95-115, February.
    16. Lauren J. Christie & Nicola Fearn & Annie McCluskey & Meryl Lovarini & Reem Rendell & Alison Pearce, 2022. "Cost-Effectiveness of Constraint-Induced Movement Therapy Implementation in Neurorehabilitation: The ACTIveARM Project," PharmacoEconomics - Open, Springer, vol. 6(3), pages 437-450, May.
    17. Linda Ryen & Stefan Lundqvist & Åsa Cider & Mats Börjesson & Maria E. H. Larsson & Lars Hagberg, 2023. "Cost-Effectiveness of Prolonged Physical Activity on Prescription in Previously Non-Complying Patients: Impact of Physical Activity Mediators," IJERPH, MDPI, vol. 20(5), pages 1-14, February.
    18. Beata Wieczorek-Wójcik & Aleksandra Gaworska-Krzemińska & Aleksander Owczarek & Michał Wójcik & Monika Orzechowska & Dorota Kilańska, 2022. "The Influence of Nurse Education Level on Hospital Readmissions—A Cost-Effectiveness Analysis," IJERPH, MDPI, vol. 19(7), pages 1-15, March.
    19. Zanfina Ademi & Kumar Pasupathi & Danny Liew, 2017. "Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 363-374, June.
    20. Ilias Goranitis & Pelham Barton & Lee J Middleton & Jonathan J Deeks & Jane P Daniels & Pallavi Latthe & Arri Coomarasamy & Suneetha Rachaneni & Shanteela McCooty & Tina S Verghese & Tracy E Roberts, 2016. "Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-18, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:23:p:16090-:d:990635. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.